Aligos Therapeutics (ALGS) Change in Account Payables (2019 - 2026)
Aligos Therapeutics (ALGS) reported Change in Account Payables of $3.7 million for Q1 2026, up 111.39% on a YoY basis from $1.7 million in Q1 2025, and up 646.64% quarter-over-quarter from -$669000.0 in Q4 2025.
Aligos Therapeutics (ALGS) Change in Account Payables (2019 - 2026) Analysis & Trends
Aligos Therapeutics has reported Change in Account Payables for 8 years, with the latest figure at $3.7 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables rose 111.39% year-over-year to $3.7 million; the trailing twelve-month figure through Mar 2026 stood at $3.3 million (up 128.79% YoY), and the FY2025 full-year result was $1.4 million, up 2512.96% from the prior year.
- Change in Account Payables for Q1 2026 stood at $3.7 million, up from -$669000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $4.0 million in Q2 2024, with the low at -$4.1 million in Q3 2024.
- Historically, Change in Account Payables has averaged $272058.8 across 5 years, with a median of $169000.0 in 2022.
- The largest YoY upside for Change in Account Payables was 849.16% in 2024 against a maximum downside of 1259.67% in 2024.
- Aligos Therapeutics' Change in Account Payables stood at $1.8 million in 2022, then tumbled by 123.42% to -$423000.0 in 2023, then jumped by 60.05% to -$169000.0 in 2024, then slumped by 295.86% to -$669000.0 in 2025, then soared by 646.64% to $3.7 million in 2026.
- The last three Change in Account Payables figures came in at $3.7 million (Q1 2026), -$669000.0 (Q4 2025), and $752000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -9.42 Mn |
| 10 | Aligos Therapeutics | 51.70 Mn | -28.13 Mn | - | 3.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.66 Mn |
| Mar 31, 2026 | 3.66 Mn |
| Dec 31, 2025 | -669,000.00 |
| Dec 31, 2025 | -669,000.00 |
| Sep 30, 2025 | 752,000.00 |
| Sep 30, 2025 | 752,000.00 |
| Jun 30, 2025 | -402,000.00 |
| Jun 30, 2025 | -402,000.00 |
| Mar 31, 2025 | 1.73 Mn |
| Mar 31, 2025 | 1.73 Mn |
| Dec 31, 2024 | -169,000.00 |
| Dec 31, 2024 | -169,000.00 |
| Sep 30, 2024 | -4.08 Mn |
| Sep 30, 2024 | -4.08 Mn |
| Jun 30, 2024 | 3.98 Mn |
| Jun 30, 2024 | 3.98 Mn |
| Mar 31, 2024 | 325,000.00 |
| Mar 31, 2024 | 325,000.00 |
| Dec 31, 2023 | -423,000.00 |
| Dec 31, 2023 | -423,000.00 |